Australia's Imugene rises on licence to expand study of cancer treatment

Imugene

19/09/2022 05:56

** Shares of Imugene  IMU.AX  rise as much as 4.6% to
A$0.230, set to mark their best session since Sept. 8 if gains
hold 
    ** Cancer-focused biopharma co receives licence required to
expand its VAXINIA Phase 1 clinical trial within Australia (https://bit.ly/3DAD8BQ)
    ** VAXINIA will be used to treat patients with metastatic or
advanced solid tumours
    ** Study aims to recruit 100 patients across about 10
clinical trial sites in the United States and Australia 
    ** Stock down ~45% this year, as of last close 
    


 (Reporting by Upasana Singh in Bengaluru)
 ((Upasana.Singh@thomsonreuters.com))